PMC:2948432 / 7090-8069 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/2948432","sourcedb":"PMC","sourceid":"2948432","source_url":"https://www.ncbi.nlm.nih.gov/pmc/2948432","text":"In this study, we have investigated the gene dosage of multiple tumor suppressors at 9p21 in formalin-fixed, paraffin-embedded (FFPE) primary melanoma tumors. Furthermore, we have investigated the relationship between reduced gene dosage at the CDKN2A locus and BRAF/NRAS mutations using tumors from patients who have relapsed and from patients with similar tumors who have not relapsed, to determine the prognostic value of these events. The presence of ulceration is an important prognostic factor for melanoma even in stage III or metastatic disease (Balch et al.,2001) and, therefore, we also assessed the associations between CDKN2A deletion and BRAF/NRAS mutation and ulceration. In other series, mitotic rate has important prognostic significance (Elder and Murphy,2008), and therefore, we also examined genetic markers in relation to mitotic rate. CDKN2A is a cyclin D kinase (CDK) inhibitor and therefore loss of CDKN2A would likely be related to increased mitotic rate.","tracks":[{"project":"2_test","denotations":[{"id":"20140953-11504745-43951730","span":{"begin":567,"end":571},"obj":"11504745"}],"attributes":[{"subj":"20140953-11504745-43951730","pred":"source","obj":"2_test"}]},{"project":"0_colil","denotations":[{"id":"20140953-11504745-957382","span":{"begin":567,"end":571},"obj":"11504745"}],"attributes":[{"subj":"20140953-11504745-957382","pred":"source","obj":"0_colil"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#93ec97","default":true},{"id":"0_colil","color":"#ec93a8"}]}]}}